CRVO · CervoMed Inc. · Metrics
$2.37
+0.06 (+2.60%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 7, 2026
The latest filing no longer states the doubt (first flagged May 15, 2026).
View the 10-Q filed Aug 7, 2026Market Cap
$34.62M
Shares
15.12M
Volume · Oct 20
134.53K
Avg daily vol (3M)
286.37K
CRVO metrics
68 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$2.29
Market cap
$34.62M
Price action
20 metricsPrice change (1W)
-8.0%
Price change (30D)
-4.1%
Price change (3M)
-17.2%
Price change (6M)
-41.8%
Price change (YTD)
-70.8%
Price change (1Y)
-67.4%
Trailing year
Price change (5Y)
—
52-week high
$9.94
52-week low
$2.24
Change from 52-week high
-76.8%
Change from 52-week low
+3.1%
Annualized volatility
115.9%
Annualized volatility (3M)
72.5%
Beta
1.8
RSI (14D)
38.2
Price vs SMA 50
-13.5%
Price vs SMA 200
-38.5%
Avg volume (3M)
292,098
Relative volume
0.7
Average dollar volume
$796,261
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
15.12M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
105.4×
reciprocal yield 0.9%
P / book
1.5
reciprocal yield 65.7%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-86.9%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
8.7×
reciprocal yield 11.6%
EV / revenue historical average (5Y)
8.7×
reciprocal yield 11.6%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-06-15
Profitability
9 metricsGross margin
—
Operating margin
-9,407.0%
Trailing 12 months
Net margin
-9,160.9%
Gross profit (TTM)
$71,667
Operating profit (TTM)
−$31.16M
Net income (TTM)
−$30.35M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$331,295
Trailing 12 months
EPS growth YoY
+4.7%
Shares change YoY
+131.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
-81.7%
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-132.2%
Return on assets
-116.8%
Debt / equity
—
Current ratio
—
EBITDA (TTM)
−$6.38M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$22.46M
Total assets
$25.99M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$27.98M
Capital expenditures (TTM)
$447,823
R&D (TTM)
$21.33M
SG&A (TTM)
—
Stock compensation (TTM)
$1.30M
R&D / revenue
6,437.7%
Stock compensation / revenue
393.0%
Ownership (13F)
9 metrics13F filers
37
13F filer change QoQ
+1
Institutional ownership
11.6%
Conviction holders (share of 13F filers)
2.7%
Crowding (high-turnover and private-fund holders)
11.2%
Private-fund adviser ownership
7.9%
Active holders' share change QoQ
+145.2%
Holder tenure
2.6
Price vs estimated holder cost
-27.4%
Ownership (registered funds)
1 metricsIndex-fund ownership
2.6%
Short interest
3 metricsShort interest
8.9%
Latest settlement · 7.1 days to cover
Days to cover
7.1d
Short-squeeze score
76 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—